Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage

BACKGROUND: Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVII...

Descripción completa

Detalles Bibliográficos
Autores principales: Kissela, Brett M, Eckman, Mark H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397434/
https://www.ncbi.nlm.nih.gov/pubmed/18489750
http://dx.doi.org/10.1186/1471-2377-8-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397434/
https://www.ncbi.nlm.nih.gov/pubmed/18489750
http://dx.doi.org/10.1186/1471-2377-8-17

Ejemplares similares